pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 41 Non-oncology: 27
Oncology: 14
Under Consideration for Negotiation 18 Non-oncology: 12
Oncology: 6
Completed Negotiations 721 With Letter of Intent: 620
Without agreement: 101
Negotiations That Were Not Pursued 105

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Awiqli Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2
Remsima SC Celltrion Healthcare Canada Ltd. Crohn's disease
Remsima SC Celltrion Healthcare Canada Ltd. Ulcerative Colitis
Evkeeza Ultragenyx Pharmaceutical Inc. Homozygous Familial Hypercholesterolemia
Libtayo Regeneron in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1
Libtayo Regeneron Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced
Libtayo Regeneron Basal cell carcinoma (BCC), locally advanced or metastatic, previously treated with a hedgehog pathway inhibitor
Orgovyx Sumitomo Pharma Canada, Inc. Advanced prostate cancer
Livmarli Mirum Pharmaceuticals Inc. Alagille syndrome
Bylvay Medison Pharma Canada Inc. Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Orladeyo BioCryst Pharmaceuticals Inc. Hereditary Angioedema
Slynd Duchesnay Inc. Contraceptive, oral
Yescarta Gilead Sciences Canada Inc. Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), in adult patients, that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Yescarta Gilead Sciences Canada Inc. Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Welireg Merck Canada Inc. Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immedi
Omvoh Eli Lilly Canada Inc. Ulcerative Colitis
Keytruda Merck Canada Neoadjuvant-adjuvant treatment of adult patients with stage III or stage IV melanoma
Keytruda Merck Canada Biliary tract carcinoma (BTC) in adult patients, locally advanced unresectable or metastatic, in combination with chemotherapy
Keytruda Merck Canada Gastric or gastroesophageal junction (GEJ) adenocarcinoma in adult patients, locally advanced unresectable or metastatic, HER2‑positive, first-line treatment in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, whose tu

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks